Back to Journals » OncoTargets and Therapy » Volume 18

Chen K, Huang X, Chen J, Zhang S. Onco Targets Ther. 2025;18:283–296.

The authors have advised that Table 1 on page 287 is incorrect. The Characteristics “Sintilimab” and “Toripalimab” listed in the PD-1 inhibitors section are interchanged.

The correct Table 1 is as follows.

Table 1 Baseline characteristics of patients

The authors apologize for the error.

Read the original article

© 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.